317 related articles for article (PubMed ID: 29198908)
21. Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer.
Graf RP; Hullings M; Barnett ES; Carbone E; Dittamore R; Scher HI
Eur Urol; 2020 Feb; 77(2):170-177. PubMed ID: 31648903
[TBL] [Abstract][Full Text] [Related]
22. Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest.
Liu HE; Vuppalapaty M; Hoerner CR; Bergstrom CP; Chiu M; Lemaire C; Che J; Kaur A; Dimmick A; Liu S; Metzner TJ; Araya M; Crouse S; Sprenger-Haussels M; Schlumpberger M; Leppert JT; Hauch S; Sollier E; Fan AC
BMC Cancer; 2024 Apr; 24(1):482. PubMed ID: 38627648
[TBL] [Abstract][Full Text] [Related]
23. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
[TBL] [Abstract][Full Text] [Related]
24. Androgen receptor isoforms expression in benign prostatic hyperplasia and primary prostate cancer.
Hillebrand AC; Pizzolato LS; Neto BS; Branchini G; Brum IS
PLoS One; 2018; 13(7):e0200613. PubMed ID: 30028845
[TBL] [Abstract][Full Text] [Related]
25. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.
Del Re M; Biasco E; Crucitta S; Derosa L; Rofi E; Orlandini C; Miccoli M; Galli L; Falcone A; Jenster GW; van Schaik RH; Danesi R
Eur Urol; 2017 Apr; 71(4):680-687. PubMed ID: 27733296
[TBL] [Abstract][Full Text] [Related]
26. Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer.
Scher HI; Graf RP; Schreiber NA; Jayaram A; Winquist E; McLaughlin B; Lu D; Fleisher M; Orr S; Lowes L; Anderson A; Wang Y; Dittamore R; Allan AL; Attard G; Heller G
JAMA Oncol; 2018 Sep; 4(9):1179-1186. PubMed ID: 29955787
[TBL] [Abstract][Full Text] [Related]
27. Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancer.
Sekino Y; Han X; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shiota M; Takeshima Y; Yasui W; Matsubara A
Urol Oncol; 2020 Oct; 38(10):795.e1-795.e8. PubMed ID: 32430253
[TBL] [Abstract][Full Text] [Related]
28. Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.
Sowalsky AG; Figueiredo I; Lis RT; Coleman I; Gurel B; Bogdan D; Yuan W; Russo JW; Bright JR; Whitlock NC; Trostel SY; Ku AT; Patel RA; True LD; Welti J; Jimenez-Vacas JM; Rodrigues DN; Riisnaes R; Neeb A; Sprenger CT; Swain A; Wilkinson S; Karzai F; Dahut WL; Balk SP; Corey E; Nelson PS; Haffner MC; Plymate SR; de Bono JS; Sharp A
Clin Cancer Res; 2022 Aug; 28(16):3509-3525. PubMed ID: 35695870
[TBL] [Abstract][Full Text] [Related]
29. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.
Nakazawa M; Lu C; Chen Y; Paller CJ; Carducci MA; Eisenberger MA; Luo J; Antonarakis ES
Ann Oncol; 2015 Sep; 26(9):1859-1865. PubMed ID: 26117829
[TBL] [Abstract][Full Text] [Related]
30. Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer.
To SQ; Kwan EM; Fettke HC; Mant A; Docanto MM; Martelotto L; Bukczynska P; Ng N; Graham LK; Parente P; Pezaro C; Mahon K; Horvath L; Todenhöfer T; Azad AA
Eur Urol; 2018 Jun; 73(6):818-821. PubMed ID: 29398263
[TBL] [Abstract][Full Text] [Related]
31. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K
Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425
[TBL] [Abstract][Full Text] [Related]
32. Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials.
Rizzo A; Mollica V; Rosellini M; Marchetti A; Ricci AD; Fiorentino M; Battelli N; Santoni M; Massari F
Pathol Res Pract; 2021 Jun; 222():153440. PubMed ID: 33857854
[TBL] [Abstract][Full Text] [Related]
33. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
Sharp A; Welti JC; Lambros MBK; Dolling D; Rodrigues DN; Pope L; Aversa C; Figueiredo I; Fraser J; Ahmad Z; Lu C; Rescigno P; Kolinsky M; Bertan C; Seed G; Riisnaes R; Miranda S; Crespo M; Pereira R; Ferreira A; Fowler G; Ebbs B; Flohr P; Neeb A; Bianchini D; Petremolo A; Sumanasuriya S; Paschalis A; Mateo J; Tunariu N; Yuan W; Carreira S; Plymate SR; Luo J; de Bono JS
Eur Urol; 2019 Nov; 76(5):676-685. PubMed ID: 31036442
[TBL] [Abstract][Full Text] [Related]
34. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
Zhu Y; Dalrymple SL; Coleman I; Zheng SL; Xu J; Hooper JE; Antonarakis ES; De Marzo AM; Meeker AK; Nelson PS; Isaacs WB; Denmeade SR; Luo J; Brennen WN; Isaacs JT
Oncogene; 2020 Nov; 39(45):6935-6949. PubMed ID: 32989253
[TBL] [Abstract][Full Text] [Related]
35. Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy.
Li H; Zhang Y; Li D; Ma X; Xu K; Ding B; Li H; Wang Z; Ouyang W; Long G; Zeng J; Liu H; Yan L; Zhang Y; Liu Z; Guan W; Hu Z; Liu C; Wan J; Wang G; Pu X; Zhang M; Guo L; An R; Qi J; Guo A; Ye Z; Liu J; Zhang X; Xu H
Eur Urol; 2021 Jun; 79(6):879-886. PubMed ID: 33579577
[TBL] [Abstract][Full Text] [Related]
36. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
Sharp A; Coleman I; Yuan W; Sprenger C; Dolling D; Rodrigues DN; Russo JW; Figueiredo I; Bertan C; Seed G; Riisnaes R; Uo T; Neeb A; Welti J; Morrissey C; Carreira S; Luo J; Nelson PS; Balk SP; True LD; de Bono JS; Plymate SR
J Clin Invest; 2019 Jan; 129(1):192-208. PubMed ID: 30334814
[TBL] [Abstract][Full Text] [Related]
37. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.
Hörnberg E; Ylitalo EB; Crnalic S; Antti H; Stattin P; Widmark A; Bergh A; Wikström P
PLoS One; 2011 Apr; 6(4):e19059. PubMed ID: 21552559
[TBL] [Abstract][Full Text] [Related]
38. Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression.
Tommasi S; Pilato B; Carella C; Lasorella A; Danza K; Vallini I; De Summa S; Naglieri E
Prostate; 2019 Jan; 79(1):54-61. PubMed ID: 30141201
[TBL] [Abstract][Full Text] [Related]
39. Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies.
Marshall CH; Chen Y; Kuo C; Cullen J; Jiang J; Rosner I; Markowski M; McLeod DG; Trock BJ; Eisenberger MA
J Urol; 2021 Sep; 206(3):623-629. PubMed ID: 34003011
[TBL] [Abstract][Full Text] [Related]
40. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.
Bernemann C; Schnoeller TJ; Luedeke M; Steinestel K; Boegemann M; Schrader AJ; Steinestel J
Eur Urol; 2017 Jan; 71(1):1-3. PubMed ID: 27471164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]